西班牙安达卢西亚地区 fostamatinib 治疗免疫性血小板减少症患者的经验——Fostasur 研究
这项在西班牙安达卢西亚开展的观察性、回顾性、多中心研究纳入 44 例成人原发性免疫性血小板减少症(ITP)患者(女性 47.7%,中位年龄 58 岁,慢性 ITP 79.5%,中位既往治疗 4 种),评估 fostamatinib 治疗至少 4 周后的疗效与安全性。开始 fostamatinib 时中位血小板计数为 15×10^9/L;2 周时总体缓解率为 56.8%,4 周、12 周和研究结束时缓解率分别为 70.5%、62.5% 和 64%。不良事件轻微,无患者因此停药。
要点
- Fostasur 研究中 fostamatinib 治疗的缓解率与关键临床试验相似。
- 2 周总体缓解率 56.8%,4 周、12 周和研究结束时分别为 70.5%、62.5% 和 64%。
- 不良事件轻微,无患者因不良事件停用 fostamatinib。
核心结论
- 这项真实世界研究显示 fostamatinib 的缓解率与关键临床试验中所见相似,同时纳入了新诊断患者并允许个体化给药。
研究设计与样本
- 观察性、回顾性、多中心研究,在西班牙安达卢西亚地区开展,纳入 44 例成人原发性 ITP 患者(女性 47.7%,中位年龄 58 岁;新诊断 ITP 6.8%,持续性 13.6%,慢性 79.5%;中位既往治疗 4 种),评估 fostamatinib 治疗至少 4 周后的情况。
主要发现
- 开始 fostamatinib 时中位血小板计数为 15×10^9/L。
- 治疗 2 周时总体缓解率(缓解加完全缓解)为 56.8%。
- 4 周、12 周和研究结束时缓解率分别为 70.5%、62.5% 和 64%。
- 不良事件轻微,无患者因不良事件停药。
- 开始 fostamatinib 的常见原因包括对既往治疗无效或不耐受、偏好口服药物、血栓史和心血管风险。
临床怎么用
- 给药根据疗效和耐受性进行个体化调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is characterized by low platelet counts (PLTs) and an increased risk of bleeding. Fostamatinib, a spleen tyrosine kinase inhibitor, has been approved as a second-line treatment for ITP. Real-world data on fostamatinib are lacking. This observational, retrospective, multicentre study, conducted in the Andalusia region of Spain, evaluated 44 adult primary ITP patients (47.7% female; median age 58 years; newly diagnosed ITP 6.8%; persistent 13.6%; chronic 79.5%; median four prior treatments) after ≥ 4 weeks of fostamatinib therapy. The median PLT at the initiation of fostamatinib was 15 × 109/L. Common reasons for starting fostamatinib were refractoriness or intolerance to prior therapy, oral medication preference, history of thrombosis and cardiovascular risk. Dosing was individualized based on efficacy and tolerance. After 2 weeks, global response rate was 56.8% (response and complete response). Response rates were 70.5%, 62.5% and 64% at 4 weeks, 12 weeks and at the end of the study respectively. Adverse events were mild, and no patients discontinued as a result. This real-world study demonstrated a response rate similar to fostamatinib as seen in the pivotal clinical trials while including newly diagnosed patients and allowing for individualized dosing.
引用
- Jiménez-Bárcenas R, García-Donas-Gabaldón G, Campos-Álvarez RM, et al. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study. Br J Haematol. 2024. PMID: 38566598. doi:10.1111/bjh.19443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。